Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to -$62.1 million.

  • Relay Therapeutics' Free Cash Flow rose 17.52% to -$62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.9 million, marking a year-over-year increase of 11.93%. This contributed to the annual value of -$251.1 million for FY2024, which is 17.51% up from last year.
  • As of Q3 2025, Relay Therapeutics' Free Cash Flow stood at -$62.1 million, which was down 12.36% from -$55.3 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Free Cash Flow registered a high of $46.2 million during Q1 2021, and its lowest value of -$89.3 million during Q4 2023.
  • Over the past 3 years, Relay Therapeutics' median Free Cash Flow value was -$69.0 million (recorded in 2023), while the average stood at -$67.9 million.
  • As far as peak fluctuations go, Relay Therapeutics' Free Cash Flow skyrocketed by 297.67% in 2021, and later slumped by 212.57% in 2022.
  • Over the past 5 years, Relay Therapeutics' Free Cash Flow (Quarterly) stood at -$40.6 million in 2021, then crashed by 46.34% to -$59.4 million in 2022, then slumped by 50.36% to -$89.3 million in 2023, then spiked by 35.20% to -$57.9 million in 2024, then rose by 17.52% to -$62.1 million in 2025.
  • Its Free Cash Flow was -$62.1 million in Q3 2025, compared to -$55.3 million in Q2 2025 and -$73.6 million in Q1 2025.